---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-039195"
form_type: "8-K"
ticker: "RNGE"
cik: "0001438943"
company_name: "RANGE IMPACT, INC."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:15:34.812181+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Range Impact sells cannabinoid drug unit Graphium for warrants and cash

## Summary
- Sold all Graphium common stock to Placer Biosciences, owned by former officers Dr. Zipp and Mr. McKilligan.
- Consideration: warrants for 25% of Placer common stock (exercise price $0.01, expiring 2034), de minimis cash, 50% of equipment sale proceeds over 12 months.
- Graphium held IP, permits, and lab equipment for early-stage cannabinoid therapeutics targeting Crohn’s disease and colitis.
- Divestiture part of strategic shift to focus on acquiring, reclaiming, and repurposing mine land in Appalachia.

## SEC filing metadata
- accession: 0001493152-24-039195
- form_type: 8-K
- ticker: RNGE
- cik: 0001438943
- company_name: RANGE IMPACT, INC.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438943/000149315224039195/0001493152-24-039195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438943/000149315224039195/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-039195
- JSON: https://secwatch.observer/filing/0001493152-24-039195.json
- Plain text: https://secwatch.observer/filing/0001493152-24-039195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.